Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
4
×
national blog main
boston
clinical trials
drugs
alnylam pharmaceuticals
aminolevulinic acid
fda
givosiran
national top stories
rna interference
roche
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
biopharma
biotech
blueprint medicines
boulder/denver blog main
boulder/denver top stories
cancer
companion diagnostic
deals
detroit blog main
detroit top stories
dna sequencing
duchenne
entrectinib
europe blog main
europe top stories
express scripts
foundation medicine
indiana blog main
indiana top stories
josh bilenker
keytruda
larotrectinib
What
medicine
4
×
second
4
×
drug
fda
rna
alnylam
approval
interference
new
pharmaceuticals
rnai
seek
speedy
ago
approved
betting
billion
biopharma
cancer
cleared
data
deal
deeper
dna
duchenne
far
fingerprint
gene
genetic
going
historic
indicated
market
matter
nasdaq
nd
nod
ok
oks
puts
Language
unset
Current search:
second
×
medicine
×
" life sciences "
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug